Abstracts tagged "rheumatoid arthritis (RA) and biologic drugs"

Abstract Number: 1330 • 2019 ACR/ARP Annual Meeting
No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years
Anja Strangfeld¹, Klaus Krüger ², Bernhard Manger ³, Christian Kneitz ⁴, Angela Zink ⁵ and Martin Schaefer ⁶, ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Rheumatologist, München, Germany, ³Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁴Rheumatologist, Schwerin, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Due to demographic changes an increasing number of persons reach an age above 70 years. Therefore, the adequate therapy of elderly patients with rheumatoid…
Abstract Number: 2345 • 2019 ACR/ARP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
C. Fernández-Díaz¹, Rafael Melero ², Javier Loricera ³, Santos Castañeda ⁴, Francisco Ortiz-Sanjuán ⁵, I. Casafont-Solé ⁶, Carmen carrasco-Cubero ⁷, A. Juan-Mas ⁸, Raquel Almodovar-Gonzalez ⁹, S. Rodriguez-Garcia ¹⁰, R. Castellanos ¹¹, O. Maiz-Alonso ¹², C. Aguilera-Cros ¹³, I. Cabezas-rodriguéz ¹⁴, EC Cervantes ¹⁵, M. Moreno ¹⁶, L. Arboleya ¹⁷, C. Montagut ¹⁸, Patricia Carreira ¹⁹, C. Ojeda-Garcia ²⁰, Gema Bonilla ²¹, T. Perez-Sandoval ²², P. Vela ²³, JL Andreu ²⁴, Susana Romero-Yuste ²⁵, A. Urruticoechea-Arana ²⁶, E. Salgado-Pérez ²⁷, Cristina Hidalgo ²⁸, Javier Narváez ²⁹, E. Raya ³⁰, MJ. Moreno-Ramos ³¹, P. Morales-Garrido ³², L. Pérez-alba ³³, Carlos Fernández-López ³⁴, Ignacio Villa ³⁵, Noelia Álvarez-Rivas ³⁶, Juan María Blanco-Madrigal ³⁷, JR Jimenez-Aberasturi ³⁸, A. Perez-Linaza ³⁹, N. Del-val-del-amo ⁴⁰, Sabela Fernández ⁴¹, A. García-valle ⁴², C.A. Peralta-Ginés ⁴³, A. Garcia-Aparicio ⁴⁴, L. Exposito-pérez ⁴⁵, N. Mena-Vazquez ⁴⁶, R. López-Sánchez ⁴⁷, B. Garcia-magallon ⁴⁸, Miguel Angel González-Gay ⁴⁹ and Ricardo Blanco ⁵⁰, ¹HU Vinalopo, Madrid, Madrid, Spain, ²Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁶HU German Trias i pujol, BAacelona, ⁷CHU de Badajoz, Badajoz, Spain, ⁸H Son Llázer, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁰HU. Clinic, Barcelona, ¹¹Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ¹²HU Donostia, Donostia, Spain, ¹³hospital virgen del rocio, Sevilla, Spain, ¹⁴HU. Río Hortega, Valladolid, Spain, ¹⁵HU Santiago de compostela, Santiago, ¹⁶Parc Tauli Hospital Universitari, Sabadell, Spain, ¹⁷Hospital Central Asturias, OViedo, ¹⁸HCU Valladolid, Valladolid, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰HU Virgen de la Macarena, Sevilla, ²¹Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ²²HU León, León, Spain, ²³Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ²⁴HU Puerta del Hierro, Madrid, ²⁵Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ²⁶HU Can Misses, Ibiza, Spain, ²⁷C.H Ourense, Ourense, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁹Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ³⁰Hospital San Cecilio, Granada, Andalucia, Spain, ³¹HU Arrixaca, Murcia, Spain, ³²Hospital San Cecilio, Granada, Spain, ³³HU San Cecilio, Granada, Spain, ³⁴Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ³⁵Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³⁷Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ³⁸HU Araba, Vitoria, Spain, ³⁹HU Puerta del Mar, Cadiz, ⁴⁰HU Navarra, Pamplona, Spain, ⁴¹Hospital Universitario San Agustín, Avilés, Asturias, Spain, ⁴²Rheumatology Department. Hospital Rio Carrión, Palencia, Spain, ⁴³HU Lozano Blesa, Zaragoza, ⁴⁴H Virgen de la salud, Toledo, Spain, ⁴⁵HU Canarias, Tenerife, Spain, ⁴⁶HU Malaga., Malaga, ⁴⁷Hospital Negrin, Tenerife, ⁴⁸H Huesca, HUesca, ⁴⁹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵⁰Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA).Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].